Company / R&D per Share
SELLAS Life Sciences Group, Inc. R&D per Share History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$0.31
FY2024
5-year range
$0.31 / $1.83
FY2020-FY2024
Trend
-72.7%
vs FY2023
Sector context
#185 of 208
Health Care
What the data says
SELLAS Life Sciences Group, Inc.'s r&d per share of $0.31 is lower than 89% of companies in the Health Care sector (FY2024). R&D per Share has fluctuated over the past 10 years, ranging from $0.22 in FY2015 to $33.52 in FY2018.
Based on SEC 10-K filings.
0.31 in FY2024 with a 5-year CAGR of -35.7%.
Declined from $0.99 to $0.31 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- -21.7%
- 5-Year CAGR
- -35.7%
- 10-Year CAGR
- -
Sector benchmark
Bottom 11% in Health CareTop 89% of 208This company $0.31 Sector average $28.82
▼
-98.9% below sector average
Key checks
Key Insights
- In FY2024, r&d per share decreased 72.7% year-over-year.
- Ranks #185 out of 208 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2018.
- Lowest r&d per share in the period was in FY2015.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.39 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $0.31 | -72.7% |
| FY2023 | $1.14 | +15.9% |
| FY2022 | $0.99 | +51.4% |
| FY2021 | $0.65 | -64.4% |
| FY2020 | $1.83 | -35.8% |
| FY2019 | $2.85 | -91.5% |
| FY2018 | $33.52 | +1193.1% |
| FY2017 | $2.59 | +84.2% |
| FY2016 | $1.41 | +552.4% |
| FY2015 | $0.22 | -14.7% |
As of FY2024 · SEC 10-K · Updated Jun 30, 2026